Biocon is currently trading at Rs. 345.50, up by 5.35 points or 1.57% from its previous closing of Rs. 340.15 on the BSE.

The scrip opened at Rs. 349.10 and has touched a high and low of Rs. 351.45 and Rs. 344.30 respectively. So far 1126885 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 303.85 on 09-Apr-2025.

Last one week high and low of the scrip stood at Rs. 367.75 and Rs. 337.95 respectively. The current market cap of the company is Rs. 56107.72 crore.

The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 29.10% and 16.45% respectively.

Biocon’s subsidiary -- Biocon Pharma has received approval from the U.S. Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg. 

The approved product is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. This approval further strengthens Biocon’s expanding diabetes portfolio, which spans oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, reinforcing the Company’s integrated approach to addressing the evolving needs of people living with diabetes globally. Dapagliflozin Tablets will be manufactured at Biocon’s FDA-approved facilities, in compliance with global quality and regulatory standards.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.